KRC-00715

CAS: 2079853-72-6 F: C25H25F3N8O3 W: 542.51

KRC-00715 is an effective oral c-Met inhibitor with an IC50 of 9.0 nM, demonstrating high selectivity in gastric cancer

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	KRC-00715 is an effective oral c-Met inhibitor with an IC50 of 9.0 nM, demonstrating high selectivity in gastric cancer cells. KRC-00715 specifically inhibits the growth of c-Met-highly expressed cell lines by inducing G1/S phase arrest, leading to a reduction in downstream signaling pathways, including Akt and Erk, as well as c-Met activity. KRC-00715, in the gastric cancer cell line Hs746, is characterized by an IC50 of 39 nM, and it selectively inhibits the proliferation of c-Met-highly expressed cell lines. KRC-00715 reduces tumor size in Hs746T xenograft mouse models[1].
Invitro	KRC-00715 具有细胞毒性 IC50 为 39 nM，是优良的 c-Met 抑制剂[1]。KRC-00715 (8，40，200，1000 nM; 3 h; wb; Hs746T，AGS) 抑制 c-Met 自磷酸化，c-Met 活性的抑制主要有助于抑制细胞的增殖[1]。KRC-00715 在 c-Met 高表达细胞系中发挥作用且在 Hs746T 细胞中 IC50 值为 39 nM，并且抑制高表达细胞系中 c-Met 自磷酸化，Akt 和 Erk 的磷酸化 (细胞毒性实验，wb)[1]。KRC-00715 (细胞周期实验; 30 nM 和 300 nM) 对 SNU-5 G1/S 的阻滞效果比 SNU-1 更为明显，30 nM 条件下的数值为 72.53 和 64.54，300 nM 的条件下数值为 73.62 和 83.64[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> KRC-00715 相关抗体: Cell Cytotoxicity Assay[1] Cell Line:
In Vivo	KRC-00715 (50mg/kg; Oral gavage (p.o.); 每日一次; 10天) 抑制在裸鼠异种移植 Hs746T 肿瘤体积增加[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	2079853-72-6
Formula	C25H25F3N8O3
Molar Mass	542.51
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Chi Hoon Park, et al. Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.BMC Cancer. 2016 Jan 22:16:35.

Cyclo(Arg-Pro) TFA